GW0742 induced a significant decrease in brain 6E10 immunoreactivity. Two-week treatment of 4.5-month-old 5XFAD mice with the PPARδ agonist GW0742 significantly reduced the 6E10 immunoreactivity in the subiculum (A) and hippocampus (B). Figures (C) and (D) depict representative images of the 6E10 immunoreactivity in the hippocampal areas of vehicle and GW0742-treated mice, respectively. GW0742 failed to reduce Iba-1 immunoreactivity in the subiculum area of the hippocampi (E) but induced a significant reduction in microgliosis as measured by Iba-1 immunoreactivity in the hippocampus (F). Figures (G) and (H) are representative images of Iba-1 immunoreactivity in hippocampal area in vehicle- (G) and GW0742- (H) treated mice. GW0742 treatment did not alter astrogliosis as measured by glial fibrillary acidic protein (GFAP) immunoreactivity in subiculum (I) or hippocampus (J). Figures (K) and (L) are representative images of GFAP immunoreactivity in vehicle- (K) and GW0742- (L) treated mice. The dotted lines outline the quantified areas of the hippocampi and the subiculum. Results are presented as mean ± SEM. VEH = vehicle- and GW0742 = GW0742-treated mice.*P < 0.05 and ***P < 0.001 as analyzed by Student’s t-test. n = 7 in vehicle- and n = 9 in GW0742-treated group. Scale bar = 400 μm.